Is Iovance Biotherapeutics a Buy?
After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.
Iovance Biotherapeutics, Inc.
IOVA
IOVA
$41.32
$2.51
6.5%
Price as of December 1, 2020, 9:00 p.m. EST
View Interactive IOVA Charts
Iovance Biotherapeutics, Inc.
Interactive Chart
News & Analysis: Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Couples Data Release With Stock Offering
The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
IOVA earnings call for the period ending March 31, 2020.
My Top Biotech Stocks to Buy in the Market Crash
The worst may be yet to come for the stock market, but these biopharma companies have promising potential.
Here's Why Iovance Biotherapeutics Jumped 51.3% in February
Rumors of a buyout swirled around the biopharma.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript
IOVA earnings call for the period ending December 31, 2019.
Here's Why Iovance Biotherapeutics Shares Soared as Much as 39.6%
Bloomberg reports that the company has been toying with the idea of a sale.
Here's Why Agenus Tumbled Today
Results from an experimental combination therapy were impressive, but they might not be impressive enough.
2 Top Biotech Stocks to Buy Right Now
These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.
Why Iovance Biotherapeutics Shares Dropped 11.8% Today
The company announced a string of deals over the weekend that failed to spark investors' optimism.
